Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obrixtamig + cisplatin + etoposide
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Obrixtamig + cisplatin + etoposide is a combination regimen under investigation for the treatment of neuroendocrine carcinomas, including small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC-L), and extrapulmonary neuroendocrine carcinomas (epNEC). **Obrixtamig** (BI 764532, HPN328) is a bispecific antibody-based T-cell engager that bridges delta-like ligand 3 (DLL3) on tumor cells and CD3 on T-cells, prompting immune-mediated cytotoxicity against DLL3-expressing cancer cells[1][2][3]. **Cisplatin** and **etoposide** are cytotoxic chemotherapy agents: cisplatin forms DNA cross-links, leading to apoptosis, while etoposide is a topoisomerase II inhibitor, preventing DNA repair and replication. Obrixtamig is being combined with cisplatin and etoposide in clinical trials to potentially enhance antitumor activity beyond standard chemotherapy alone, particularly in patients with DLL3-positive tumors[1][2].
- Other names
- BI 764532BI764532BI-764532HPN328HPN-328HPN 328obrixtamig
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on obrixtamig + cisplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obrixtamig + cisplatin + etoposide.